Biogen Appoints Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation
November 02 2017 - 4:30PM
Business Wire
Biogen (Nasdaq: BIIB) announced today the appointment of Chirfi
Guindo as Executive Vice President and Head of Global Marketing,
Market Access and Customer Innovation.
In this newly created role, Mr. Guindo will lead Biogen’s global
functions of Marketing and Asset Teams, Market Access and Customer
Innovation. He will report to Michel Vounatsos, CEO of Biogen,
will be a member of the Executive Committee and will be based in
Cambridge, Mass. His appointment takes effect November 7, 2017.
Mr. Guindo brings 27 years of experience in the global
pharmaceutical industry and has held several leadership positions
at Merck (known as MSD outside Canada and the USA) in Canada, the
USA, France, Africa and the Netherlands. He worked in several
disciplines including Finance, Sales & Marketing, General
Management and Global Strategy / Product Development in specialty,
acute and hospital care. Most recently Mr. Guindo was President
& Managing Director of Merck Canada.
Mr. Guindo graduated with a degree in Engineering from Ecole
Centrale de Paris (France) and obtained an MBA in Finance /
Economics from New York University / Stern School of Business
(USA).
“I am pleased to join Biogen, one of the oldest independent
biotech companies, which is widely recognized for its expertise in
treating neurological diseases,” said Mr. Guindo. “I believe that
my extensive experience gives me a unique perspective that will
enable me to identify opportunities where Biogen can deliver even
greater value to patients, our customers and society.”
“I am excited to welcome Chirfi who is a seasoned global
pharmaceutical leader in our industry,” said Mr. Vounatsos. “I look
forward to working together as we further Biogen’s leadership in MS
and SMA, plan for our Alzheimer’s disease franchise and pursue
future pipeline opportunities.”
About BiogenAt Biogen, our mission is clear: we are
pioneers in neuroscience. Biogen discovers, develops and delivers
worldwide innovative therapies for people living with serious
neurological and neurodegenerative diseases. Founded in 1978 as one
of the world’s first global biotechnology companies by Charles
Weissman and Nobel Prize winners Walter Gilbert and Phillip Sharp,
today Biogen has the leading portfolio of medicines to treat
multiple sclerosis; has introduced the first and only approved
treatment for spinal muscular atrophy; and is focused on advancing
neuroscience research programs in Alzheimer’s disease and dementia,
neuroimmunology, movement disorders, neuromuscular disorders, pain,
ophthalmology, neuropsychiatry, and acute neurology. Biogen also
manufactures and commercializes biosimilars of advanced biologics.
We routinely post information that may be important to investors on
our website at www.biogen.com. To learn more, please visit
www.biogen.com and follow us on social media – Twitter, LinkedIn,
Facebook, YouTube.
Biogen Safe HarborThis press release contains
forward-looking statements, made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
including statements relating to our business activities, our
strategy and plans, the potential of our commercial business and
pipeline programs and the expected benefits from Mr. Guindo’s
appointment as Executive Vice President and Head of Global
Marketing, Market Access and Customer Innovation. These
forward-looking statements may be accompanied by words such as
“aim,” “anticipate,” “believe,” “could,” “estimate,” “except,”
“forecast,” “intend,” “may,” “plan,” “potential,” “possible,”
“will” and other words and terms of similar meaning. Drug
development and commercialization involve a high degree of risk,
and only a small number of research and development programs result
in commercialization of a product. You should not place undue
reliance on these statements.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including, without limitation: risks relating to
management and key personnel changes; failure to compete
effectively; difficulties in obtaining and maintaining adequate
coverage, pricing and reimbursement for our products; potential
future healthcare reforms; the occurrence of adverse safety events;
failure to protect and enforce our data, intellectual property and
other proprietary rights and uncertainties relating to intellectual
property claims and challenges; uncertainty of success in
developing, licensing or acquiring other product candidates or
additional indications for existing products; delay in approval of
our drug candidates; product liability claims; and third party
collaboration risks. The foregoing sets forth many, but not all, of
the factors that could cause actual results to differ from our
expectations in any forward-looking statement. Investors should
consider this cautionary statement, as well as the risk factors
identified in Biogen’s most recent annual or quarterly report and
in other reports Biogen has filed with the U.S. Securities and
Exchange Commission. These statements are based on our current
beliefs and expectations and speak only as of the date of this
press release. We do not undertake any obligation to publicly
update any forward-looking statements, whether as a result of new
information, future developments or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171102006389/en/
BiogenMEDIA CONTACT:Matt Fearer, +1
781-464-3260public.affairs@biogen.comorINVESTOR CONTACT:Matt
Calistri, +1 781-464-2442IR@biogen.com
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2023 to Apr 2024